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Neurodegenerative diseases are one of the main causes of worldwide disability and decreased quality of life. 
A link between neurodegeneration and obesity is opening novel research avenues in the search for therapeutic 
approaches. Unfortunately, current available treatments for both pathologies remain ineffective. Therefore, 
it is important to generate appropriate models to evaluate the relationship between obesity and 
neurodegeneration. The metabolic changes caused by obesity are able to modulate the central nervous system 
by altering the synaptic plasticity. In this study, we have investigated the changes in synaptic plasticity at areas 
implicated in cognitive function, such as the hippocampus and prefrontal Tau. GSK3β is a key enzyme 
responsible for the fine balance between the phosphorylated and not phosphorylated forms of Tau, 
modulating synaptic plasticity in these areas. Different endocannabinoid (ECs) system are able to interact and 
modify the activity of GSK3β. By molecular, biochemical and morphological studies, we found remarkable 
changes in the expression of phosphorylated tau form in hippocampus and prefrontal cortex of leptin knockout 
ob/ob mice which represent a model of obesity by mimicking the leptin inefficacy in the brain of mice made 
obese by a high fat diet. Furthermore, we found elevation of 2-AG and OX-A content in the hippocampus of 
ob/ob confirming that OX-A and 2-AG (2-arachidonoylglycerol) are able interplayers to increase or decrease, 
respectively, the phosphorylation of tau in opposite way. Unraveling the functional crosstalk between ECs and 
OX system in the regulation of Tau phosphorylation of in areas of the brain involved in cognitive function could 
reveal novel molecular players and pathways that might result in drug able targets. 
 
 
